Wolverine Trading
ONCT

Wolverine Trading’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Wolverine Trading’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-7
Closed -$8K – 5336
2016
Q3 		$8K Buy
+7
New +$6.11K ﹤0.01% 4541

Other funds holding ONCT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
FHA
First Horizon Advisors Memphis, Tennessee $3.85B AUM 16.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wolverine Trading's ONCT Position: Q4 2016 in Review

Wolverine Trading sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2016, closing a stake of 7 shares — an estimated $8K sold.

Wolverine Trading first reported a position in ONCT in Q3 2016 and held it in 1 quarter. The position peaked at $8K in Q3 2016. 21 funds tracked by Wall St. Rank hold ONCT as of Q4 2016.

  • Wolverine Trading reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
  • Wolverine Trading sold 7 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2016, an estimated $8K.
  • Wolverine Trading first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q3 2016 and held it in 1 quarter.
  • Wolverine Trading's Oncternal Therapeutics, Inc. Common Stock position peaked at $8K in Q3 2016.
  • 21 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2016.

Based on Wolverine Trading's 13F filing for Q4 2016, filed 14 Feb 2017.